Truex, Nicholas L.
Holden, Rebecca L.
Wang, Bin-You
Chen, Pu-Guang
Hanna, Stephanie
Hu, Zhuting
Shetty, Keerthi
Olive, Oriol
Neuberg, Donna
Hacohen, Nir
Keskin, Derin B.
Ott, Patrick A.
Wu, Catherine J.
Pentelute, Bradley L.
Article History
Received: 25 June 2019
Accepted: 23 September 2019
First Online: 20 January 2020
Competing interests
: B.L.P. is a founder of Amide Technologies and Resolute Bio. C.J.W. is a founder of Neon Therapeutics and member of its scientific advisory board. D.B.K. has previously advised Neon Therapeutics and owns equity in Aduro Biotech, Agenus, Ampliphi BioSciences, Biomarin Pharmaceutical, Bristol-Myers Squibb, Celldex Therapeutics, Editas Medicine, Exelixis, Gilead Sciences, IMV, Lexicon Pharmaceuticals, Sangamo Therapeutics and Stemline Therapeutics. N.H. is a founder of Neon Therapeutics and member of its scientific advisory board and an advisor for IFM therapeutics. P.A.O. has received research funding from and has advised Neon Therapeutics, Bristol-Myers Squibb, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, Array, AstraZeneca/MedImmune, Armo BioSciences and Roche/Genentech.